Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 21, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Sept. 20, 2024 -- Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, according to a study published online Sept. 18 in the New England Journal of Medicine to coincide with the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.

Andrea B. Apolo, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues conducted a phase 3 trial involving patients with high-risk muscle-invasive urothelial carcinoma. Participants were randomly assigned to receive pembrolizumab (200 mg) every three weeks for one year or to undergo observation after radical surgery (354 and 348 patients, respectively). In the intention-to-treat population, the coprimary end points were disease-free and overall survival.

Patients were followed for a median of 44.8 months for disease-free survival as of July 5, 2024. The researchers found that median disease-free survival was 29.6 and 14.2 months with pembrolizumab and observation, respectively (hazard ratio for disease progression or death, 0.73). Regardless of attribution, grade 3 or higher adverse events occurred in 50.7 and 31.6 percent of patients in the pembrolizumab and observation groups, respectively.

"Taking the data in total, adjuvant checkpoint inhibitor therapy lengthens disease-free survival in certain patients with high-risk muscle-invasive urothelial cancer," the authors write.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-09-21 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords